Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip’s Top Five Stories Of 2018

Executive Summary

A look back at the Scrip stories that piqued the most interest for our readers in 2018. 

Advertisement

Related Content

Pfizer Consumer Combo Deal Frees Capital For GSK Pharma Investment
‘Drastic’ Japan Price Reforms Hitting R&D Incentives, Plans - EFPIA
AbbVie Defends Humira With Aggressive Discount In First EU Tender
Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
Momenta Is Exiting Biosimilars; Is That A Bellwether For Biosimilar Sentiment?
Who's Promised What: A Guide To Pharma Drug Pricing Pledges
Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump
Takeda, Shire Finally Seal £46bn Deal
Japan Price Reforms - Major Takeaways
FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124411

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel